COMMUNIQUÉS West-GlobeNewswire

IMU Biosciences Appoints Dr. Carlos Paya as Non-Executive Director, Strengthening its Board of Directors
20/11/2025
PRESS RELEASE London, UK, 20 November 2025 — IMU Biosciences (or “the Company”), a biotechnology company decoding the immune system to drive next generation health outcomes, today announced the appointment of Dr. Carlos [...]
Burning Rock Reports Third Quarter 2025 Financial Results
20/11/2025
GUANGZHOU, China, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the [...]
Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates
20/11/2025
Total revenues of €127.0 million compared to €116.6 million in the first nine months of 2024 Cash and cash equivalents of €143.5 million at end of September 2025 Financial flexibility enhanced with successful debt [...]
Valneva publie ses résultats financiers des neuf premiers mois de 2025 et fait un point sur ses activités
20/11/2025
Chiffre d’affaires de 127,0 millions d’euros contre 116,6 millions d’euros sur les neuf premiers mois de 2024 Trésorerie de 143,5 millions d’euros à fin septembre 2025 Flexibilité financière accrue grâce au succès du [...]
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
20/11/2025
Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance rolled forward to +5-6% cc CAGR for 2025-2030, following upgrade of 2024-2029 guidance to +6% cc 1 Peak sales guidance upgraded for Kisqali and Scemblix [...]
Third quarter 2025 update: IBA is highly confident to meet FY2025 guidance, and strengthens financing structure
20/11/2025
Louvain-la-Neuve, Belgium, 20 November 2025 - IBA (Ion Beam Applications SA), the world leader in particle accelerator technology, shares its business update for the third quarter of 2025. Group Overview Equipment order [...]
Déclaration Intermédiaire Troisième Trimestre : IBA très confiante dans la réalisation de sa guidance 2025, renforcement de la structure de financement
20/11/2025
Louvain-la-Neuve, Belgique, le 20 novembre 2025 - IBA (Ion Beam Applications SA), le leader mondial des technologies d’accélération de particules, publie aujourd'hui la revue de ses activités pour le troisième trimestre [...]
Scientific Industries Announces Third Quarter 2025 Results And Launch of VIVID’s New AI-Powered Feature
20/11/2025
TORBAL DIVISION SALES UP 15% YTD LAUNCH OF VIVID’S FIRST AI-POWERED FEATURE SECOND GENERATION VIVID-ONE LAUNCH SCHEDULED FOR Q1 CY26 Investor Call to be held Thursday, November 20 th at 11:00 a.m. Eastern Time BOHEMIA, [...]
FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
20/11/2025
HOUSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the [...]
Profusa Announces Third Quarter Business and Financial Highlights
19/11/2025
Recapitalization reduced net debt to $14 million as of October 31; achieved key milestones to deliver potential 2026 revenue target BERKELEY, Calif, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “ [...]
Apollomics Announces Settlement of Cayman Litigation
19/11/2025
FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement” or the “Agreement”) [...]
Extendicare to Expand its Home Health Care Business by Acquiring CBI Home Health for $570 Million in Cash Consideration
19/11/2025
Extendicare also announces $200 million bought deal private placement equity offering Not for distribution to U.S. news wire services or dissemination in the United States. MARKHAM, ONTARIO, Nov. 19, 2025 (GLOBE [...]
FDA Pilots Faster Clarifications to Meeting Minutes
19/11/2025
Silver Spring, Md., Nov. 19, 2025 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today announced a pilot program designed to streamline communications with sponsors following formal meetings. Through the [...]
InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference
19/11/2025
MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced plans to participate in a fireside discussion [...]
Heartflow to Participate in the Piper Sandler 37th Annual Healthcare Conference
19/11/2025
MOUNTAIN VIEW, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today announced that members [...]
Arch Biopartners Closes Non-Brokered Private Placement
19/11/2025
TORONTO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc ., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has closed a non-brokered private placement offering of 576,923 [...]
Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025
19/11/2025
Financial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center of Nevada operations Management to host conference call today at 5:00 pm [...]
ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results
19/11/2025
ZyVersa is advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases, and Inflammasome ASC [...]
EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications
19/11/2025
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing flexibility for more [...]

Pages